Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery
Abstract Background 89Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909 keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guid...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-05-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13550-025-01247-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849325919885328384 |
|---|---|
| author | Adnan Chowdhury Clément Morgat Clement Bailly John Sunderland Stephen A. Graves Andrew M. Scott Sean Baker Beverley F. Holman |
| author_facet | Adnan Chowdhury Clément Morgat Clement Bailly John Sunderland Stephen A. Graves Andrew M. Scott Sean Baker Beverley F. Holman |
| author_sort | Adnan Chowdhury |
| collection | DOAJ |
| description | Abstract Background 89Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909 keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guide assessment of the radiation risk and necessary safety guidelines, we present laboratory dose rate measurements of 89Zr syringes and vials, and dose rates measurements made during the ZIRCON clinical trial ([89Zr]Zr-girentuximab) to evaluate healthcare provider exposure during administration, imaging, and surgical procedures. Results The maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66 mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1 m from patients who received [89Zr]Zr-girentuximab had an average of 3.90 µSv/h at imaging. During surgery, waste measured below background levels, and a bed assistant 0.8 m from the patient received a 5 µSv/h whole-body dose rate. The excised kidney measured 6 µSv/h at 5 cm. Conclusions Our results demonstrate low radiation exposure levels associated with 89Zr handling and exposure to the patient. With potential integration of 89Zr into clinical practice, appropriate radiation safety guidelines are needed. Dose rate measurements can help guide development of best practices and site-specific protocols. Clinical trial number: not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019. |
| format | Article |
| id | doaj-art-862d7ae9fc5e4f91bf5266235a5e6ba4 |
| institution | Kabale University |
| issn | 2191-219X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Research |
| spelling | doaj-art-862d7ae9fc5e4f91bf5266235a5e6ba42025-08-20T03:48:18ZengSpringerOpenEJNMMI Research2191-219X2025-05-0115111110.1186/s13550-025-01247-1Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgeryAdnan Chowdhury0Clément Morgat1Clement Bailly2John Sunderland3Stephen A. Graves4Andrew M. Scott5Sean Baker6Beverley F. Holman7Royal Free London NHS Foundation TrustINCIA UMR 5287, University of BordeauxNantes Université, Inserm, CNRS, Université d’Angers, CRCI2NADepartment of Radiology, University of IowaDepartment of Radiology, University of IowaDepartment of Molecular Imaging and Therapy, Austin Health and Faculty of Medicine, University of MelbourneRoyal Free London NHS Foundation TrustRoyal Free London NHS Foundation TrustAbstract Background 89Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909 keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guide assessment of the radiation risk and necessary safety guidelines, we present laboratory dose rate measurements of 89Zr syringes and vials, and dose rates measurements made during the ZIRCON clinical trial ([89Zr]Zr-girentuximab) to evaluate healthcare provider exposure during administration, imaging, and surgical procedures. Results The maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66 mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1 m from patients who received [89Zr]Zr-girentuximab had an average of 3.90 µSv/h at imaging. During surgery, waste measured below background levels, and a bed assistant 0.8 m from the patient received a 5 µSv/h whole-body dose rate. The excised kidney measured 6 µSv/h at 5 cm. Conclusions Our results demonstrate low radiation exposure levels associated with 89Zr handling and exposure to the patient. With potential integration of 89Zr into clinical practice, appropriate radiation safety guidelines are needed. Dose rate measurements can help guide development of best practices and site-specific protocols. Clinical trial number: not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019.https://doi.org/10.1186/s13550-025-01247-1Radiation protectionZirconium-89RadiopharmaceuticalsRadiation safetyGirentuximab |
| spellingShingle | Adnan Chowdhury Clément Morgat Clement Bailly John Sunderland Stephen A. Graves Andrew M. Scott Sean Baker Beverley F. Holman Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery EJNMMI Research Radiation protection Zirconium-89 Radiopharmaceuticals Radiation safety Girentuximab |
| title | Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery |
| title_full | Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery |
| title_fullStr | Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery |
| title_full_unstemmed | Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery |
| title_short | Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery |
| title_sort | radiation protection considerations with 89zr zr girentuximab pet and surgery |
| topic | Radiation protection Zirconium-89 Radiopharmaceuticals Radiation safety Girentuximab |
| url | https://doi.org/10.1186/s13550-025-01247-1 |
| work_keys_str_mv | AT adnanchowdhury radiationprotectionconsiderationswith89zrzrgirentuximabpetandsurgery AT clementmorgat radiationprotectionconsiderationswith89zrzrgirentuximabpetandsurgery AT clementbailly radiationprotectionconsiderationswith89zrzrgirentuximabpetandsurgery AT johnsunderland radiationprotectionconsiderationswith89zrzrgirentuximabpetandsurgery AT stephenagraves radiationprotectionconsiderationswith89zrzrgirentuximabpetandsurgery AT andrewmscott radiationprotectionconsiderationswith89zrzrgirentuximabpetandsurgery AT seanbaker radiationprotectionconsiderationswith89zrzrgirentuximabpetandsurgery AT beverleyfholman radiationprotectionconsiderationswith89zrzrgirentuximabpetandsurgery |